Initial pediatric cardiac experience with decellularized allograft patches.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 22364987.
- Also identified by DOI 10.1016/j.athoracsur.2011.09.039.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study examines use patterns, early outcomes, and technical surgical adaptability of a newly approved decellularized allograft pulmonary artery patch for right ventricular outflow tract reconstructions in neonates and infants, including primary operations and reoperations. The study includes the 44 consecutive initial patients in which 46 patches were used for cardiovascular reconstruction between September 2009 and September 2010. Recorded variables include sex, age at operation, adverse outcome end points (eg, death, stenosis, aneurysm), congenital diagnoses, postoperative complications, and number, type, and location of patches. Patients were a mean age of 290±343 days at operation, and 54.5% were boys. Three types of patch were used: 58.7% thin, 21.7% thick, and 19.6% hemipulmonary. No device-related deaths or adverse events occurred. A biopsy specimen of one patch at elective reoperation demonstrated active recellularization, with no inflammation. These patches have a wide range of applicability. Handling and technical flexibility is excellent and superior to standard options. There appears to be potential for autologous revitalization of the tissue.
Medical subject headings
- Pulmonary Artery
- Ventricular Outflow Obstruction